TY - JOUR
T1 - Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma
AU - Kambach, Diane M.
AU - Halim, Alan S.
AU - Gesine Cauer, A.
AU - Sun, Qian
AU - Tristan, Carlos A.
AU - Celiku, Orieta
AU - Kesarwala, Aparna H.
AU - Shankavaram, Uma
AU - Batchelor, Eric
AU - Stommel, Jayne M.
N1 - Funding Information:
This work was supported by the US National Cancer Institute Center for Cancer Research (NCI-CCR) Intramural Research Program ZIA BC 011441 (to J.M.S).
PY - 2017
Y1 - 2017
N2 - A hallmark of cellular transformation is the evasion of contact-dependent inhibition of growth. To find new therapeutic targets for glioblastoma, we looked for pathways that are inhibited by high cell density in astrocytes but not in glioma cells. Here we report that glioma cells have disabled the normal controls on cholesterol synthesis. At high cell density, astrocytes turn off cholesterol synthesis genes and have low cholesterol levels, but glioma cells keep this pathway on and maintain high cholesterol. Correspondingly, cholesterol pathway upregulation is associated with poor prognosis in glioblastoma patients. Densely-plated glioma cells increase oxygen consumption, aerobic glycolysis, and the pentose phosphate pathway to synthesize cholesterol, resulting in a decrease in reactive oxygen species, TCA cycle intermediates, and ATP. This constitutive cholesterol synthesis is controlled by the cell cycle, as it can be turned off by cyclin-dependent kinase inhibitors and it correlates with disabled cell cycle control though loss of p53 and RB. Finally, glioma cells, but not astrocytes, are sensitive to cholesterol synthesis inhibition downstream of the mevalonate pathway, suggesting that specifically targeting cholesterol synthesis might be an effective treatment for glioblastoma.
AB - A hallmark of cellular transformation is the evasion of contact-dependent inhibition of growth. To find new therapeutic targets for glioblastoma, we looked for pathways that are inhibited by high cell density in astrocytes but not in glioma cells. Here we report that glioma cells have disabled the normal controls on cholesterol synthesis. At high cell density, astrocytes turn off cholesterol synthesis genes and have low cholesterol levels, but glioma cells keep this pathway on and maintain high cholesterol. Correspondingly, cholesterol pathway upregulation is associated with poor prognosis in glioblastoma patients. Densely-plated glioma cells increase oxygen consumption, aerobic glycolysis, and the pentose phosphate pathway to synthesize cholesterol, resulting in a decrease in reactive oxygen species, TCA cycle intermediates, and ATP. This constitutive cholesterol synthesis is controlled by the cell cycle, as it can be turned off by cyclin-dependent kinase inhibitors and it correlates with disabled cell cycle control though loss of p53 and RB. Finally, glioma cells, but not astrocytes, are sensitive to cholesterol synthesis inhibition downstream of the mevalonate pathway, suggesting that specifically targeting cholesterol synthesis might be an effective treatment for glioblastoma.
KW - Cell cycle
KW - Cholesterol metabolism
KW - Glioblastoma
KW - Oxygen utilization
KW - Pre-clinical cancer therapies
UR - http://www.scopus.com/inward/record.url?scp=85014088188&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014088188&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.14740
DO - 10.18632/oncotarget.14740
M3 - Article
AN - SCOPUS:85014088188
SN - 1949-2553
VL - 8
SP - 14860
EP - 14875
JO - Oncotarget
JF - Oncotarget
IS - 9
ER -